Stemtech Corporation Announces Uplist to OTCQB, Maintains Focus on Expansion and Transparency
Stemtech (STEK) has announced its uplisting to OTCQB, marking a significant milestone in its commitment to transparency and investor confidence. As a pioneer in stem cell nutrition, Stemtech is expanding its global footprint across the United States, Mexico, Ecuador, Canada, and Taiwan. The company offers innovative products in stem cell nutrition, skin care, oral care, and recently announced pet care technologies.
The global stem cells market is projected to grow from $14.92 billion in 2023 to $49.26 billion by 2034, with a CAGR of 11.47%. Stemtech's CEO, Charles S. Arnold, emphasizes the increasing awareness of stem cell benefits and the company's reasonably priced, life-maintenance system. With decades of research, Stemtech focuses on developing all-natural, plant-based stem cell products to enhance human and pet health, offering both health solutions and income-earning opportunities.
Stemtech (STEK) ha annunciato il suo passaggio a OTCQB, segnando un traguardo significativo nel suo impegno verso la trasparenza e la fiducia degli investitori. In quanto pioniere nella nutrizione a base di cellule staminali, Stemtech sta espandendo la sua presenza globale negli Stati Uniti, Messico, Ecuador, Canada e Taiwan. L'azienda offre prodotti innovativi nel campo della nutrizione a base di cellule staminali, cura della pelle, cura orale e ha recentemente annunciato tecnologie per la cura degli animali domestici.
Si prevede che il mercato globale delle cellule staminali crescerà da 14,92 miliardi di dollari nel 2023 a 49,26 miliardi di dollari entro il 2034, con un tasso di crescita annuale composto (CAGR) dell'11,47%. Il CEO di Stemtech, Charles S. Arnold, sottolinea la crescente consapevolezza dei benefici delle cellule staminali e il sistema di mantenimento della vita dell'azienda a prezzi ragionevoli. Con decenni di ricerca, Stemtech si concentra sullo sviluppo di prodotti a base di cellule staminali completamente naturali e vegetali per migliorare la salute umana e degli animali domestici, offrendo sia soluzioni sanitarie che opportunità di guadagno.
Stemtech (STEK) ha anunciado su ascenso a OTCQB, marcando un hito significativo en su compromiso con la transparencia y la confianza de los inversores. Como pionero en nutrición de células madre, Stemtech está expandiendo su huella global en Estados Unidos, México, Ecuador, Canadá y Taiwán. La compañía ofrece productos innovadores en nutrición de células madre, cuidado de la piel, cuidado bucal y recientemente anunció tecnologías de cuidado de mascotas.
Se proyecta que el mercado global de células madre crecerá de $14.92 mil millones en 2023 a $49.26 mil millones para 2034, con una tasa compuesta anual de crecimiento (CAGR) del 11.47%. El CEO de Stemtech, Charles S. Arnold, enfatiza la creciente conciencia sobre los beneficios de las células madre y el sistema de mantenimiento de vida de la empresa a precios razonables. Con décadas de investigación, Stemtech se centra en desarrollar productos de células madre completamente naturales y a base de plantas para mejorar la salud humana y de las mascotas, ofreciendo tanto soluciones de salud como oportunidades de ingresos.
스템텍(STEK)은 OTCQB로의 상장을 발표하며 투명성과 투자자 신뢰에 대한 의지를 나타내는 중요한 이정표를 세웠습니다. 스템셀이 영양학의 선구자로서 스템텍은 미국, 멕시코, 에콰도르, 캐나다, 대만 전역으로 글로벌 입지를 확장하고 있습니다. 이 회사는 스템셀 영양, 피부 관리, 구강 관리 분야에서 혁신적인 제품을 제공하며 최근에는 반려동물 관리 기술도 발표했습니다.
글로벌 스템셀 시장은 2023년 149억 2천만 달러에서 2034년에는 492억 6천만 달러로 성장할 것으로 예상되며, 연평균 성장률(CAGR)은 11.47%입니다. 스템텍의 CEO인 찰스 S. 아놀드는 스템셀의 이점에 대한 인식이 높아지고 있으며, 회사의 합리적인 가격으로 제공되는 생명 유지 시스템을 강조합니다. 수십 년의 연구를 통해 스템텍은 인간과 반려동물의 건강을 증진시키기 위해 모두 자연적이고 식물 기반의 스템셀 제품을 개발하는 데 집중하고 있으며, 건강 솔루션과 수익 창출 기회를 동시에 제공합니다.
Stemtech (STEK) a annoncé son passage à l'OTCQB, marquant une étape importante dans son engagement envers la transparence et la confiance des investisseurs. En tant que pionnier de la nutrition par cellules souches, Stemtech étend son empreinte mondiale aux États-Unis, au Mexique, en Équateur, au Canada et à Taïwan. L'entreprise propose des produits innovants dans le domaine de la nutrition par cellules souches, des soins de la peau, des soins bucco-dentaires et a récemment annoncé des technologies de soins pour animaux de compagnie.
Le marché mondial des cellules souches devrait croître de 14,92 milliards de dollars en 2023 à 49,26 milliards de dollars d'ici 2034, avec un taux de croissance annuel composé (CAGR) de 11,47%. Le PDG de Stemtech, Charles S. Arnold, souligne la prise de conscience croissante des avantages des cellules souches et le système de maintien de vie à prix raisonnable de l'entreprise. Fort de plusieurs décennies de recherche, Stemtech se concentre sur le développement de produits à base de cellules souches 100 % naturels et d'origine végétale pour améliorer la santé humaine et animale, offrant à la fois des solutions de santé et des opportunités de revenus.
Stemtech (STEK) hat seine Listung an OTCQB bekannt gegeben, was einen bedeutenden Meilenstein in seinem Engagement für Transparenz und das Vertrauen der Investoren darstellt. Als Pionier in der Ernährung mit Stammzellen erweitert Stemtech seine globale Präsenz in den USA, Mexiko, Ecuador, Kanada und Taiwan. Das Unternehmen bietet innovative Produkte in der Stammzellernährung, Hautpflege, Zahnpflege und hat kürzlich Technologien für die Haustierpflege angekündigt.
Der globale Markt für Stammzellen wird erwartet, von 14,92 Milliarden US-Dollar im Jahr 2023 auf 49,26 Milliarden US-Dollar bis 2034 zu wachsen, mit einer jährlichen Wachstumsrate (CAGR) von 11,47%. Der CEO von Stemtech, Charles S. Arnold, betont das zunehmende Bewusstsein für die Vorteile von Stammzellen und das angemessen preisgefügte Lebensunterhaltssystem des Unternehmens. Mit Jahrzehnten an Forschung konzentriert sich Stemtech auf die Entwicklung von 100 % natürlichen pflanzenbasierten Stammzellprodukten zur Verbesserung der Gesundheit von Mensch und Haustier, und bietet sowohl Gesundheitslösungen als auch Einkommensmöglichkeiten an.
- Uplisting to OTCQB, potentially increasing investor visibility and confidence
- Expansion into multiple international markets
- Introduction of new pet care technologies, diversifying product portfolio
- Operating in a rapidly growing global stem cells market (projected CAGR of 11.47% from 2023 to 2034)
- Decades of research and development in stem cell nutrition
- None.
NAPLES, FL / ACCESSWIRE / September 4, 2024 / ("STEK") Stemtech Corporation, the pioneer and trailblazer in the stem cell nutrition sector, is proud to announce that OTC Markets has approved us to quote as an OTCQB stock, symbolizing a commitment to transparency and investor confidence. As we consolidate our footprint in the United States, Mexico, Ecuador, Canada and Taiwan, this milestone is a testament to our dedication to global health through groundbreaking stem cell nutrition, skin care, oral care and as recently announced on August 22, pet care technologies.
The global stem cells market is poised for substantial growth, projected to increase from
Stemtech Chairman and CEO, Charles S. Arnold states "with the passage of time, there is an enhanced awareness, and more people are becoming educated about the power, the miracle of stem cells and the benefits of helping your body help itself. Our niche products are reasonably priced, and our life-maintenance system is something everyone should be taking to improve their quality of life".
With decades of research and development, Stemtech is the knowledge leader in the stem cell nutrition industry. Our expertise spans the development of products that naturally enhance the body's ability to renew and repair itself, using scientifically validated approaches that underscore our commitment to quality, efficacy, and safety.
At Stemtech, our focus remains on enhancing human and soon pet health by harnessing the potential of all-natural, plant-based stem cell products, offering solutions that not only meet current health challenges but also anticipate future needs. Join us as we lead the charge in a revolution to naturally enhance anti-aging, longevity, and quality of life worldwide. This, combined with our income-earning business opportunity makes Stemtech a very attractive model for health and wealth.
ABOUT STEMTECH
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry.
FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 27, 2024. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its source.
Investor Relations:
Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Phone: +1 623-261-9046
Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com
SOURCE: Stemtech Corporation
View the original press release on accesswire.com
FAQ
What is Stemtech 's new stock market status as of September 4, 2024?
In which countries does Stemtech (STEK) operate as of 2024?
What is the projected growth of the global stem cells market according to Stemtech's (STEK) press release?
What new product category did Stemtech (STEK) announce on August 22, 2024?
